BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heffron AS, McIlwain SJ, Amjadi MF, Baker DA, Khullar S, Armbrust T, Halfmann PJ, Kawaoka Y, Sethi AK, Palmenberg AC, Shelef MA, O'Connor DH, Ong IM. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol 2021;19:e3001265. [PMID: 34143766 DOI: 10.1371/journal.pbio.3001265] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Grötzinger C. Applications of Peptide Microarrays in Autoantibody, Infection, and Cancer Detection. Methods in Molecular Biology 2023. [DOI: 10.1007/978-1-0716-2732-7_1] [Reference Citation Analysis]
2 Hotop SK, Reimering S, Shekhar A, Asgari E, Beutling U, Dahlke C, Fathi A, Khan F, Lütgehetmann M, Ballmann R, Gerstner A, Tegge W, Cicin-Sain L, Bilitewski U, McHardy AC, Brönstrup M. Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2. Emerg Microbes Infect 2022;11:1037-48. [PMID: 35320064 DOI: 10.1080/22221751.2022.2057874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Liu S, Stauft CB, Selvaraj P, Chandrasekaran P, D’agnillo F, Chou C, Wu WW, Lien CZ, Meseda CA, Pedro CL, Starost MF, Weir JP, Wang TT. Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. Nat Commun 2022;13:6792. [DOI: 10.1038/s41467-022-34571-4] [Reference Citation Analysis]
4 Wang Q, Ning J, Chen Y, Li B, Shi L, He T, Zhang F, Chen X, Zhai A, Wu C. The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1008420] [Reference Citation Analysis]
5 Gutiérrez LJ, Tosso RD, Zarycz MNC, Enriz RD, Baldoni HA. Epitopes mapped onto SARS-CoV-2 receptor-binding motif by five distinct human neutralising antibodies. Molecular Simulation. [DOI: 10.1080/08927022.2022.2111421] [Reference Citation Analysis]
6 Mikolajek H, Weckener M, Brotzakis ZF, Huo J, Dalietou EV, Le Bas A, Sormanni P, Harrison PJ, Ward PN, Truong S, Moynie L, Clare DK, Dumoux M, Dormon J, Norman C, Hussain N, Vogirala V, Owens RJ, Vendruscolo M, Naismith JH. Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes. Proc Natl Acad Sci U S A 2022;119:e2205412119. [DOI: 10.1073/pnas.2205412119] [Reference Citation Analysis]
7 Kakkanas A, Karamichali E, Koufogeorgou EI, Kotsakis SD, Georgopoulou U, Foka P. Targeting the YXXΦ Motifs of the SARS Coronaviruses 1 and 2 ORF3a Peptides by In Silico Analysis to Predict Novel Virus—Host Interactions. Biomolecules 2022;12:1052. [DOI: 10.3390/biom12081052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ng KW, Faulkner N, Finsterbusch K, Wu M, Harvey R, Hussain S, Greco M, Liu Y, Kjaer S, Swanton C, Gandhi S, Beale R, Gamblin SJ, Cherepanov P, McCauley J, Daniels R, Howell M, Arase H, Wack A, Bauer DLV, Kassiotis G. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci Transl Med 2022;14:eabn3715. [PMID: 35895836 DOI: 10.1126/scitranslmed.abn3715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Dolan KA, Dutta M, Kern DM, Kotecha A, Voth GA, Brohawn SG. Structure of SARS-CoV-2 M protein in lipid nanodiscs.. [DOI: 10.1101/2022.06.12.495841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gregory DJ, Vannier A, Duey AH, Roady TJ, Dzeng RK, Pavlovic MN, Chapin MH, Mukherjee S, Wilmot H, Chronos N, Charles RC, Ryan ET, LaRocque RC, Miller TE, Garcia-Beltran WF, Thierauf JC, Iafrate AJ, Mullenbrock S, Stump MD, Wetzel RK, Polakiewicz RD, Naranbhai V, Poznansky MC. Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19. Virulence 2022;13:890-902. [PMID: 35587156 DOI: 10.1080/21505594.2022.2073025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Auerswald H, Eng C, Lay S, In S, Eng S, Vo HTM, Sith C, Cheng S, Delvallez G, Mich V, Meng N, Sovann L, Sidonn K, Vanhomwegen J, Cantaert T, Dussart P, Duong V, Karlsson EA. Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2. Front Med 2022;9:864972. [DOI: 10.3389/fmed.2022.864972] [Reference Citation Analysis]
12 Mishra M, Zahra A, Chauhan LV, Thakkar R, Ng J, Joshi S, Spitzer ED, Marcos LA, Lipkin WI, Mishra N. A Short Series of Case Reports of COVID-19 in Immunocompromised Patients. Viruses 2022;14:934. [PMID: 35632677 DOI: 10.3390/v14050934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Felbinger N, Trudil D, Loomis L, Ascione R, Siragusa G, Haba S, Rastogi S, Mucci A, Claycomb M, Snowberger S, Luke B, Francesconi S, Tsang S. Epitope Mapping of SARS-CoV-2 Spike Protein Reveals Distinct Antibody Binding Activity of Vaccinated and Infected Individuals.. [DOI: 10.1101/2022.04.13.487697] [Reference Citation Analysis]
14 Martynova E, Hamza S, Markelova M, Garanina E, Davidyuk Y, Shakirova V, Kaushal N, Baranwal M, Stott-Marshall RJ, Foster TL, Rizvanov A, Khaiboullina S. Immunogenic SARS-CoV-2 S and N Protein Peptide and Cytokine Combinations as Biomarkers for Early Prediction of Fatal COVID-19. Front Immunol 2022;13:830715. [PMID: 35386707 DOI: 10.3389/fimmu.2022.830715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mcguire BE, Mela JE, Thompson VC, Cucksey LR, Stevens CE, Mcwhinnie RL, Winkler DFH, Pelech S, Nano FE. Escherichia coli recombinant expression of SARS-CoV-2 protein fragments. Microb Cell Fact 2022;21. [DOI: 10.1186/s12934-022-01753-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Herrscher C, Eymieux S, Gaborit C, Blasco H, Marlet J, Stefic K, Roingeard P, Grammatico-Guillon L, Hourioux C. ELISA-Based Analysis Reveals an Anti-SARS-CoV-2 Protein Immune Response Profile Associated with Disease Severity. J Clin Med 2022;11:405. [PMID: 35054099 DOI: 10.3390/jcm11020405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Errico JM, Adams LJ, Fremont DH. Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology 2022. [DOI: 10.1016/bs.ai.2022.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Naqvi RA, Shukla D, Naqvi AR. SARS‐CoV‐2 targeting by RNAi and host complement inhibition: A two‐pronged subterfuge for COVID‐19 treatment. Immun Inflamm Dis 2022;10:22-25. [DOI: 10.1002/iid3.549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ng KW, Faulkner N, Finsterbusch K, Wu M, Harvey R, Hussain S, Greco M, Liu Y, Kjaer S, Swanton C, Gandhi S, Beale R, Gamblin SJ, Cherepanov P, Mccauley J, Daniels R, Howell M, Arase H, Wack A, Bauer DL, Kassiotis G. Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccination.. [DOI: 10.1101/2021.11.30.470568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Amjadi MF, Adyniec RR, Gupta S, Bashar SJ, Mergaert AM, Braun KM, Moreno GK, O'Connor DH, Friedrich TC, Safdar N, McCoy SS, Shelef MA. Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination. medRxiv 2021:2021. [PMID: 34790984 DOI: 10.1101/2021.11.02.21265750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Tang Q, Owens RJ, Naismith JH. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2. Viruses 2021;13:2214. [PMID: 34835020 DOI: 10.3390/v13112214] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
22 Deutsch EW, Omenn GS, Sun Z, Maes M, Pernemalm M, Palaniappan KK, Letunica N, Vandenbrouck Y, Brun V, Tao SC, Yu X, Geyer PE, Ignjatovic V, Moritz RL, Schwenk JM. Advances and Utility of the Human Plasma Proteome. J Proteome Res 2021. [PMID: 34672606 DOI: 10.1021/acs.jproteome.1c00657] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
23 Martin-Vicente M, Almansa R, Martínez I, Tedim AP, Bustamante E, Tamayo L, Aldecoa C, Gómez JM, Renedo G, Berezo JÁ, Cedeño JA, Mamolar N, García Olivares P, Herrán-Monge R, Cicuendez R, Enríquez P, Ortega A, Jorge N, Doncel C, de la Fuente A, Bustamante-Munguira J, Muñoz-Gómez MJ, González-Rivera M, Puertas C, Más V, Vázquez M, Pérez-García F, Rico-Feijoo J, Martín S, Motos A, Fernandez-Barat L, Eiros JM, Dominguez-Gil M, Ferrer R, Barbé F, Trapiello W, Kelvin DJ, Bermejo-Martin JF, Resino S, Torres A. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J Intern Med 2021. [PMID: 34611927 DOI: 10.1111/joim.13386] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
24 Hachim A, Kavian N, Valkenburg SA. Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets. Curr Opin Virol 2021;50:139-46. [PMID: 34464844 DOI: 10.1016/j.coviro.2021.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
25 Markosian C, Staquicini DI, Dogra P, Dodero-rojas E, Tang FHF, Smith TL, Contessoto VG, Libutti SK, Wang Z, Cristini V, Whitford PC, Burley SK, Onuchic JN, Pasqualini R, Arap W. Apropos of Universal Epitope Discovery for COVID-19 Vaccines: A Framework for Targeted Phage Display-Based Delivery and Integration of New Evaluation Tools.. [DOI: 10.1101/2021.08.30.458222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]